Current Funding Opportunities
Upcoming
BioCanRx Open Call for Proposals
BioCanRx is excited to share an advance notice about our upcoming Open Call for Proposals. This $6M investment will be aimed at advancing promising cancer immunotherapies and enabling technologies toward the clinic, and supporting the adoption of these therapies into the Canadian healthcare system.
Full program details and application materials will be released on Wednesday, June 17, 2026.
This call for research proposals will seek applications to the following funding programs:
Enabling Studies Program
Up to $750,000, up to 3 years
50% matching required
- BioCanRx will fund up to 50% of total eligible project costs, to a maximum contribution of $750,000. The remaining 50% must be provided as matching funds from eligible partners.
- Prepare and position novel cancer immunotherapies and enabling technologies for clinical testing in patients, including GMP manufacturing and process development. Enabling Studies projects should result in either a complete Health Canada CTA submission packages or Quality (Chemistry and Manufacturing) packages.
Clinical Trials Program
Up to $1,000,000, up to 3 years
60% matching required
- BioCanRx will fund up to $1,000,000, representing up to 40% of total eligible project costs. The remaining 60% of project costs must be provided as matching funds from an eligible partner.
- Investigator-led Phase I/II clinical trials of novel cancer immunotherapies that have been substantially developed in Canada.
Clinical, Social and Economic Impact (CSEI) Program
Up to $215,000, up to 3 years
- Identify and address the facilitators and barriers to the adoption and integration of these therapies into Canadian clinical practice and healthcare systems.
Core Facilities Program
Up to $120,000 per year, up to 2 years
- Supports manufacturing or translational research services that support the advancement and production of cancer immunotherapies.
Linked Applications Favoured
CSEI applications may be submitted as standalone projects; however, applications that are linked with Enabling or Clinical Trials proposals currently funded or applying to this competition will be assessed more favourably.
Core Facilities will be evaluated on demonstrated evidence of planned collaborations and scope of work across multiple currently funded or proposed Enabling Studies or Clinical Trial projects.
Eligibility
Funded research team members (i.e., principal investigators) must be either:
a) based at a Canadian academic or research institution and must be eligible to receive Tri-Agency funding
b) Indigenous organization or government.
Key Components by Stage
Component | Required at LOI Stage | Required for Full Application |
| Project Description | 1-page scientific summary | Detailed full proposal |
| Project Team | Principal Investigators, Co-Investigators | Principal Investigators, Co-Investigators, Collaborators, Industry Partners |
| Budget | Budget requested per principal investigator | Detailed budget |
| Partnerships | Actual/Anticipate/Desired | Actual partners with Letters of Support |
| Partnership with Persons with Lived and/or Living Experience (PWLE)* | No | Yes |
| Milestones & Deliverables | No | Yes |
| Product/Platform Development Trajectory | No | Yes |
| Training & Mentorship | No | Yes |
| Inclusive Research Design (EDI) | No | Yes |
| Intellectual Property | No | Yes |
| Research Security | No | Yes – including signed STRA forms |
*Applicants are encouraged to contact BioCanRx early in the application process if they need support engaging with patient partners.
Key Dates
Call launch: June 17, 2026
Letter of Intent (LOI) submission deadline: July 29, 2026
Notification of LOI results and invitation to Full Application: Early October, 2026
Full application submission deadline: December 4, 2026
Notice of Award: Early March, 2027
Funding award start date: March 31, 2027
Informational Webinar
Join us for an informational webinar to learn more about this funding competition.
Date & Time: Thursday, June 25, 2026, 1:00 PM ET
If you have questions please contact Megan Mahoney, Director of Scientific Affairs and Training Programs at memahoney@biocanrx.com.